Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | MAP3K14 | Q99558 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15748777 | 0.87 | MAPT (0.56) | MAPTMAP3K14THRB | |
| SCHEMBL17192446 | 0.87 | MAPT (0.49) | MAPTMAP3K14LMNATHRB | |
| SCHEMBL15748811 | 0.86 | MAPT (0.55) | MAPTMAP3K14KDM4EKMT2ATHRB | |
| SCHEMBL17192449 | 0.85 | MAPT (0.54) | MAPTMAP3K14LMNATHRB | |
| SCHEMBL17192448 | 0.85 | MAPT (0.53) | MAPTMAP3K14LMNAKDM4ETHRB | |
| SCHEMBL17192447 | 0.85 | MAPT (0.54) | MAPTMAP3K14LMNATHRB | |
| SCHEMBL15748815 | 0.84 | MAPT (0.53) | MAPTMAP3K14LMNAKDM4ETHRB | |
| SCHEMBL17192436 | 0.83 | MAPT (0.51) | MAPTMAP3K14KMT2ATHRB | |
| SCHEMBL15748795 | 0.82 | MAPT (0.78) | MAPTMAP3K14LMNAKDM4ETHRB | |
| SCHEMBL15748846 | 0.81 | MAPT (0.58) | MAPTMAP3K14LMNAKDM4ETHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676779-B2 | Small molecule CFTR correctors | DISCOVERYBIOMED, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676779-B2 | Small molecule CFTR correctors | DISCOVERYBIOMED, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150299206-A1 | SMALL MOLECULE CFTR CORRECTORS | DISCOVERYBIOMED, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299206-A1 | SMALL MOLECULE CFTR CORRECTORS | DISCOVERYBIOMED, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| WO-2014081820-A1 | SMALL MOLECULE CFTR CORRECTORS | DISCOVERYBIOMED, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299206-A1 | SMALL MOLECULE CFTR CORRECTORS | CFTR, CLCN2, SLC26A4 | MAPT 4258/4885MAP3K14 3729/4885LMNA 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.